Indications for: SILIQ

Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and unresponsive to other systemic therapies.

Adult Dosage:

Give by SC inj into thigh, abdomen (except for area around navel), outer area of upper arm; rotate inj sites. 210mg at Weeks 0, 1, and 2 followed by 210mg every 2 weeks. If adequate response not achieved after 12–16 weeks, consider discontinuing.

Children Dosage:

Not established.

SILIQ Contraindications:

Crohn’s disease.

Boxed Warning:

Suicidal ideation and behavior.

SILIQ Warnings/Precautions:

Risk of suicidal ideation and behavior. History of depression or suicidality. May increase risk of infections. Chronic or history of recurrent infection: consider the risks/benefits. If a serious infection develops or is not responding to standard therapy, monitor closely and discontinue until resolves. Evaluate for TB infection prior to initiating; monitor for active TB during and after therapy. Patients with active TB infection: do not initiate. History of latent or active TB; consider anti-TB therapy prior to initiation. Discontinue if Crohn’s disease develops. Pregnancy. Nursing mothers.

SILIQ Classification:

Interleukin-17A antagonist.

SILIQ Interactions:

Avoid concomitant live vaccines. Concomitant CYP450 substrates with a narrow therapeutic index (eg, warfarin, cyclosporine); monitor and consider adjusting dose.

Adverse Reactions:

Arthralgia, headache, fatigue, diarrhea, oropharyngeal pain, nausea, myalgia, inj site reactions, influenza, neutropenia, tinea infections.


Available only through a restricted program under a REMS called the SILIQ REMS Program. For more information, visit or call (855) 511-6135.



Generic Drug Availability:


How Supplied:

Single-dose prefilled syringes—2